The FDA has approved GE Healthcare’s Q.Clear, a technology that GE says improves accuracy when assessing a patient’s response to treatment.

FDA approved GE Healthcare's radioactive diagnostic drug Vizamyl for use with PET scans in patients with Alzheimer's disease and dementia.

GE Healthcare axquires U-Systems Inc., developer of the Automated Breast Ultrasound, a system used as a supplement to mammography for asymptomatic women with dense breasts and no prior interventions.

GE Healthcare and RadNet have partnered to identify the most efficient, cost-effective approaches for breast cancer detection.

In this podcast, Tom Gentile, president and CEO at GE Healthcare Systems, explains that “the whole focus of imaging is moving beyond the quality of the image.” Patient care, physician productivity and reimbursement take on a renewed focus in light of healthcare reform efforts internationally, he says.

Wireless x-ray detectors have come into vogue and are now available from a half dozen vendors. They are being offered singly, as a digital upgrade for analog x-ray systems, for example, or as the core of portable and advanced fixed radiography systems. GE Healthcare is among those offering a portfolio of such choices. But GE is putting a twist on its wireless detector, dubbed the FlashPad, one that company execs say will prevent what could be a ticklish problem in the future. This potential problem stems from the success of digital radiography.

GE Healthcare jumped ahead of competitors in the race to cut patient dose with the commercial release in 2008 of its Adaptive Statistical Iterative Reconstruction (ASIR), the first software to clean up CT images and, in the process, allow dramatic reductions -- up to 50% -- in patient radiation dose. In the first day of this year’s ISCT symposium, iterative reconstruction was hailed repeatedly as the leading solution to the hottest issue in CT patient safety.


Subscribe to
Please Wait 20 seconds or click here to close